132 results on '"Tang, Meina"'
Search Results
2. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
3. Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
4. Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers
5. An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers
6. Monoclonal Antibodies: From Structure to Therapeutic Application
7. Expression and clinical association of MFG-E8 and TAM receptors in diabetic patients with different stages of microvascular complication: An experimental study
8. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
9. Targeted sequencing and functional analysis reveal brain-size-related genes and their networks in autism spectrum disorders
10. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
11. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis
12. Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
13. Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
14. Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
15. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
16. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
17. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration
18. Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis
19. Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis
20. Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
21. A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis
22. A Guide to Rational Dosing of Monoclonal Antibodies
23. Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development
24. The Effect Analysis Based on Least Square Method on Meteorological Factors to Residential Electricity Consumption in Fujian Province
25. Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies
26. P035 ETROLIZUMAB TREATMENT MODULATES SOLUBLE MADCAM-1 LEVELS IN SERUM IN PATIENTS WITH CROHN’S DISEASE
27. P035 ETROLIZUMAB TREATMENT MODULATES SOLUBLE MADCAM-1 LEVELS IN SERUM IN PATIENTS WITH CROHN’S DISEASE
28. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis
29. Etrolizumab Demonstrated no Difference Among Doses in Symptomatic and Endoscopic-Based Evaluation of Remission in Anti-TNF-α Naïve Patients in a Post hoc Analysis of the Phase 2 Ulcerative Colitis Trial (Eucalyptus)
30. De novo genic mutations among a Chinese autism spectrum disorder cohort
31. Short‐Term Efficacy Reliably Predicts Long‐Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model‐Based Meta‐Analysis
32. Etrolizumab Treatment Modulates MAdCAM-1 Levels in Serum in Ulcerative Colitis Patients
33. Etrolizumab Treatment Does Not Modify Levels of VCAM-1 in Ulcerative Colitis Patients
34. FDG-PET Imaging for Oxidized LDL in Stable Atherosclerotic Disease: A Phase II Study of Safety, Tolerability, and Anti-Inflammatory Activity
35. Su1935 - Etrolizumab Demonstrated no Difference Among Doses in Symptomatic and Endoscopic-Based Evaluation of Remission in Anti-TNF-α Naïve Patients in a Post hoc Analysis of the Phase 2 Ulcerative Colitis Trial (Eucalyptus)
36. Etrolizumab Population Pharmacokinetics (Pop PK) and Covariate Analysis in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
37. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)
38. Sa1241 Pharmacology of Etrolizumab in a Phase 2 Study in Moderate-to-Severely Active Ulcerative Colitis
39. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
40. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial
41. Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis
42. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody : Implications for trial design of antiangiogenic antibodies
43. An Engineered Human IgG1 Antibody with Longer Serum Half-Life
44. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer
45. Corrigendum to “Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration” [J. Autoimmun. 21 (2004) 283–293]
46. Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates
47. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration
48. Modeling comparative effectiveness studies: An example using a phase IV intravenous nicardipine versus labetalol in patients with uncontrolled hypertension trial.
49. A randomised phase I study of etrolizumab (rhuMAb ß7) in moderate to severe ulcerative colitis.
50. A Guide to Rational Dosing of Monoclonal Antibodies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.